Asia Pacific
Refine Search
Biotechnology
A subsidiary of WuXi AppTec and fellow Chinese firm Coherent Biopharma have announced the signing of a strategic partnership agreement, building on a successful previously-signed collaboration. 1 December 2021
Biotechnology
Chinese biotechs used to prefer late-clinical stage assets when seeking in-licensing targets for a quick launch in China, but this is no longer the case. 1 December 2021
Biotechnology
Shares of Chinese biotech Zai Lab Limited closed down 7% at HK$562 yesterday, even though the company announced that the Phase III PRIME study of Zejula (niraparib) as maintenance therapy met its primary endpoint. 1 December 2021
Biotechnology
Canada and USA-based biotech Chinook Therapeutics today announced the formation of SanReno Therapeutics, a joint venture with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China, to develop, manufacture and commercialize kidney disease therapies in China, Hong Kong, Macau, Taiwan and Singapore (the Territory). 30 November 2021
Biotechnology
Shares of Belgian cell therapy developer Bone Therapeutics jumped by a quarter over the weekend, following news of a deal with Link Health Pharma. 29 November 2021
Biotechnology
Japanese drug majors Takeda Pharmaceutical and Sumitomo Dainippon Pharma announced today that Takeda will succeed the manufacturing and marketing approval and the marketing rights of Replagal (agalsidase alfa) for Fabry disease, an α-galactosidase enzyme intravenous (IV) infusion, as of February 15, 2022. 26 November 2021
Biosimilars
Japanese mid-size drugmaker Mochida Pharmaceutical and Ayumi Pharmaceutical announced that Adalimumab BS MA (adalimumab biosimilar, code: LBAL) has now been launched in Japan as the NHI (National Health Insurance) drug price has been listed today. 25 November 2021
Biotechnology
Japanese drugmaker Ono Pharmaceutical and its partner Bristol Myers Squibb have announced the approval for the use of Opdivo (nivolumab) in two new indications in Japan. 25 November 2021
Biotechnology
The European Commission (EC) has approved Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy, says Chinese biotech BeiGene. 24 November 2021
Pharmaceutical
Multinationals corporations (MNCs) have been actively adding China to their multicenter global clinical studies in recent years, it was made clear at a recent meeting. 24 November 2021
Biotechnology
French pharma major Sanofi has inked an agreement with Chinese tech giant Baidu, aimed at improving the company’s product design processes. 23 November 2021
Biotechnology
Neurocrine Biosciences and Japanese firm Sosei Heptares have agreed a strategic collaboration and licensing deal to develop muscarinic receptor agonists which the US company will study in schizophrenia, dementia and other neuropsychiatric disorders. 22 November 2021
Biotechnology
SCG Cell Therapy plans to establish Singapore as its international hub for cell therapy research, manufacturing and clinical development to deliver products across Asia Pacific, the USA, Europe and the world. 19 November 2021
Biotechnology
Japanese drugmaker Daiichi Sankyo today announced positive top-line results from the global pivotal QuANTUMFirst Phase III trial evaluating quizartinib, a highly potent and selective FLT3 inhibitor, in patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). 19 November 2021
Biotechnology
China’s biotech industry enjoyed significant growth in the past several years, but major bottlenecks are looming as Chinese biotechs aims for a global expansion, said speakers at the two-day event Chinatrials on November 11 in Shanghai. 17 November 2021
Biotechnology
The neuromyelitis optica spectrum disorder (NMOSD) therapeutics market is highly genericized, with corticosteroids and immunosuppressants currently accounting for the highest portion of prescribed drugs in China. 16 November 2021
Biotechnology
Of the companies developing gene therapies in Japan, Takeda is leading the way, according to data and analytics company GlobalData. 15 November 2021
Biotechnology
Japanese drugmaker Ono Pharmaceutical closed trading today up 2.4% at 2,464 yen, after announcing that it entered into the settlement agreement with Dr Tasuku Honjo to resolve the litigation raised by him regarding the Osaka District Court 2020 (Wa), No 5608 claiming dividends related to the third-party litigation, following the Court settlement recommendation. 12 November 2021
Biotechnology
French rare diseases company Dynacure has entered a long-term strategic development and commercialization agreement with Japanese drugmaker Nippon Shinyaku. 11 November 2021
Biotechnology
Japanese pharma major Chugai Pharmaceutical says it has filed an application with the Ministry of Health, Labor and Welfare (MHLW) for approval of additional indication for the anti-coagulation factor IXa/X humanized bispecific monoclonal antibody/coagulation factor VIII substitute Hemlibra (emicizumab [genetical recombination]) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in people with acquired blood coagulation factor VIII deficiency. 11 November 2021
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze